The Research Progress of Direct KRAS G12C Mutation Inhibitors

Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ai, Li, Min, Fang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262225/
https://www.ncbi.nlm.nih.gov/pubmed/34257597
http://dx.doi.org/10.3389/pore.2021.631095
_version_ 1783719150116405248
author Yang, Ai
Li, Min
Fang, Mingzhi
author_facet Yang, Ai
Li, Min
Fang, Mingzhi
author_sort Yang, Ai
collection PubMed
description Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research.
format Online
Article
Text
id pubmed-8262225
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82622252021-07-12 The Research Progress of Direct KRAS G12C Mutation Inhibitors Yang, Ai Li, Min Fang, Mingzhi Pathol Oncol Res Society Journal Archive Abstract: KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize progress in the development of direct KRAS G12C mutation inhibitors, current relevant drugs under study and challenges that need to be considered in future research. Frontiers Media S.A. 2021-04-23 /pmc/articles/PMC8262225/ /pubmed/34257597 http://dx.doi.org/10.3389/pore.2021.631095 Text en Copyright © 2021 Yang, Li and Fang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Society Journal Archive
Yang, Ai
Li, Min
Fang, Mingzhi
The Research Progress of Direct KRAS G12C Mutation Inhibitors
title The Research Progress of Direct KRAS G12C Mutation Inhibitors
title_full The Research Progress of Direct KRAS G12C Mutation Inhibitors
title_fullStr The Research Progress of Direct KRAS G12C Mutation Inhibitors
title_full_unstemmed The Research Progress of Direct KRAS G12C Mutation Inhibitors
title_short The Research Progress of Direct KRAS G12C Mutation Inhibitors
title_sort research progress of direct kras g12c mutation inhibitors
topic Society Journal Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262225/
https://www.ncbi.nlm.nih.gov/pubmed/34257597
http://dx.doi.org/10.3389/pore.2021.631095
work_keys_str_mv AT yangai theresearchprogressofdirectkrasg12cmutationinhibitors
AT limin theresearchprogressofdirectkrasg12cmutationinhibitors
AT fangmingzhi theresearchprogressofdirectkrasg12cmutationinhibitors
AT yangai researchprogressofdirectkrasg12cmutationinhibitors
AT limin researchprogressofdirectkrasg12cmutationinhibitors
AT fangmingzhi researchprogressofdirectkrasg12cmutationinhibitors

Ejemplares similares